Skip to main content

Table 2 Open scratch area of U2OS cells treated with putative migration inhibitors. The scratch area at time 0 was set 100%; *** p < 0.001, ** p < 0.01, * p < 0.05; n = number of repetitions. / = cells detached from flask surface

From: In vitro wound healing of tumor cells: inhibition of cell migration by selected cytotoxic alkaloids

Compound Concentration (nM) 24 h   48 h   72 h   n
Paclitaxel Control 41.03 ± 27.83   11.91 ± 14.40   6.09 ± 8.54   6
10,000 75.67 ± 28.21   70.15 ± 25.93 *** 69.49 ± 25.96 *** 6
2000 64.68 ± 20.47   57.75 ± 17.49 *** 61.11 ± 17.56 *** 6
400 59.24 ± 16.44   53.24 ± 14.03 *** 54.84 ± 17.46 *** 6
80 58.47 ± 13.84   50.23 ± 13.39 *** 49.62 ± 14.53 *** 6
16 48.24 ± 12.56   30.49 ± 18.99   26.34 ± 18.47 * 6
1.6 42.11 ± 27.84   15.68 ± 11.85   4.79 ± 5.37   4
0.16 42.37 ± 19.51   12.86 ± 7.46   2.89 ± 4.23   3
Vinblastine Control 43.80 ± 32.59   10.22 ± 13.33   4.35 ± 6.95   4
5500 72.66 ± 19.76   57.06 ± 15.12 ** 70.21 ± 14.25 *** 4
1100 65.92 ± 31.03   58.11 ± 29.74 * 62.65 ± 36.28 * 4
220 67.60 ± 27.12   60.92 ± 23.69 ** 61.14 ± 22.50 ** 4
44 63.52 ± 28.10   55.48 ± 30.19 * 50.97 ± 33.90 * 4
8.8 69.83 ± 23.52   57.55 ± 30.94 * 55.31 ± 32.09 * 4
0.88 60.74   25.08   21.46   2
0.088 30.21   4.30   1.44   2
Colchicine Control 48.05 ± 24.45   14.30 ± 14.71   7.31 ± 8.94   5
10,000 68.25 ± 24.54   61.62 ± 34.50 * 63.70 ± 33.17 ** 5
2000 60.03 ± 25.98   47.87 ± 23.46 * 51.51 ± 32.26 * 5
400 51.41 ± 25.58   45.61 ± 24.09 * 42.70 ± 27.24 * 5
80 57.52 ± 23.55   52.54 ± 21.60 * 49.97 ± 27.97 * 5
16 48.62 ± 25.82   37.68 ± 25.16   37.71 ± 26.11 * 5
Compound Concentration (nM) 24 h   48 h   72 h   n
Podophyllo-
toxin
Control 11.66 ± 3.82   2.22 ± 2.36   0.43 ± 0.75   3
10,000 65.10 ± 4.24 *** 76.78 ± 1.37 *** 71.37 ± 5.90 *** 3
2000 70.81 ± 28.15 * 66.87 ± 15.93 ** 84.08 ± 18.24 ** 3
400 58.66 ± 6.67 *** 60.56 ± 2.13 *** 63.58 ± 12.85 ** 3
80 66.88 ± 6.17 *** 62.97 ± 5.34 *** 79.59 ± 14.17 *** 3
16 42.41 ± 1.51 *** 34.57 ± 10.57 ** 52.73 ± 8.81 *** 3
3.2 10.45 ± 14.19   0   0   3
0.64 15.70 ± 22.11   0   0   3
Sanguinarine Control 39.69 ± 13.67   10.73 ± 10.21   4.19 ± 7.67   4
5000 /   /   /   5
1000 39.62 ± 12.17   19.70 ± 5.54   13.10 ± 5.47   5
200 35.96 ± 18.07   18.12 ± 20.85   13.96 ± 20.04   5
40 29.66 ± 7.64   6.43 ± 7.75   4.37 ± 6.48   5
8 28.96 ± 15.04   5.07 ± 7.42   2.39 ± 4.84   5
Chelerythrine Control 39.69 ± 13.67   10.73 ± 10.21   4.19 ± 7.67   4
12,000 84.35 ± 23.35 * /   /   5
2400 34.43 ± 12.35   10.83 ± 14.73   9.34 ± 16.31   5
480 42.79 ± 13.29   15.89 ± 19.22   10.02 ± 18.69   5
96 29.69 ± 18.00   11.70 ± 21.10   9.28 ± 19.95   5
19.5 30.33 ± 17.73   9.07 ± 18.47   7.64 ± 16.94   5
Chelidonine Control 44.80 ± 16.45   20.16 ± 22.85   14.38 ± 23.73   5
20,000 57.98 ± 11.72   43.41 ± 24.82   44.06 ± 30.05   5
4000 44.59 ± 15.78   25.26 ± 23.38   24.46 ± 31.62   5
800 45.80 ± 17.05   23.94 ± 23.20   21.03 ± 24.67   5
160 39.21 ± 12.32   15.26 ± 15.19   12.04 ± 16.10   5
32 30.50 ± 14.01   7.77 ± 11.29   8.22 ± 16.72   5
Homoharring-
tonine
Control 3.76 ± 2.83   0.31 ± 0.69   0.26 ± 0.58   3
8000 78.98 ± 12.39 *** /   /   3
1600 74.23 ± 20.66 ** 68.25 ± 15.17 ** /   3
320 70.09 ± 6.42 *** 72.37 ± 7.95 *** 75.60 ± 7.17 *** 3
64 85.25 ± 16.02 *** 86.73 ± 12.13 *** 83.94 ± 12.26 *** 3
12.8 39.11 ± 7.84 ** 28.99 ± 6.44 ** 29.76 ± 7.19 ** 3
2.56 13.45 ± 5.53   2.68 ± 3.97   1.95 ± 3.38   3
0.5 19.08 ± 5.65 * 4.31 ± 1.71   3.95 ± 3.51   3
0.1 2.18 ± 0.85   0   0   3
Doxorubicin Control 30.29 ± 15.09   5.06 ± 4.76   0.36 ± 0.62   3
20,000 86.77 ± 11.70 ** 94.33 ± 5.34 *** /   3
10,000 71.22 ± 4.93 * 76.25 ± 6.40 *** 73.47 ± 4.82 *** 3
5000 31.19 ± 2.67   11.32 ± 6.42   7.27 ± 4.59   3
2500 27.93 ± 17.02   6.43 ± 7.73   0.65 ± 1.12   3
1250 21.82 ± 17.07   4.76 ± 6.55   0.58 ± 1.01   3
  1. Data are presented as the mean ± SD.